Adaptimmune Therapeutics Plc - ADR (NASDAQ:ADAP) stock was among today's market movers, concluding trading lower 5.62% to $1.68 on June 21.

318,609 shares traded hands in comparison to the 30-day daily average of 467,539 shares.

The company's stock dropped 52.53% so far in 2022.

Adaptimmune shares have traded in a range between $1.26 and $6.86 over the past twelve months.

For technical charts, analysis, and more on Adaptimmune visit the company profile.

About Adaptimmune Therapeutics Plc - ADR

Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products for people with cancer. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors.

To get more information on Adaptimmune Therapeutics Plc - ADR and to follow the company's latest updates, you can visit the company's profile page here: Adaptimmune Therapeutics Plc - ADR's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Trending Articles

Will Mining Stocks Fall Further?

3 Reasons To Be Optimistic About the Global Shipping Industry

The Best Laid Plans of Mice and Men — Part II

Why I’m Buying the 'New' Value Stocks